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International Patent Rights and
Biotechnology: Should the United States
Promote Technology Transfer to
Developing Countries?
TARA KOWALSKI*

I. INTRODUCTION

Florence Wambugu, a native African, spent years trying to
improve production of sweet potatoes in Africa through
traditional plant breeding. Sweet potatoes are a staple crop in
Kenya, but viruses and pests plague this valuable food source. 1
After years of research, Wambugu realized she would be unable to
develop virus-resistant potatoes using traditional plant breeding.
Meanwhile, scientists in St. Louis, Missouri had already created
virus-resistant crops through biotechnology. 2 These scientists
shared their knowledge with Wambugu and supported her efforts
to develop virus-resistant sweet potatoes. In 2001, Wambugu
initiated field tests of genetically modified (GM) potatoes in
Kenya. As her research progresses, Wambugu anticipates that
Kenyan farmers will soon be able to grow virus-resistant sweet
potatoes. Such a development could increase sweet potato yields
by enough to feed an additional ten million people. 3 Although
Wambugu's story demonstrates the important role that

* J.D., University of California at Davis; B.A., University of California at San
Diego. Special thanks to Professor Holly Doremus for her insightful comments and to the
Loyola of Los Angeles International and Comparative Law Review staff for their helpful
editing and suggestions.
1. Florence Wambugu, Taking the Food Out of Our Mouths, WASH. POST, Aug. 26,
2001, at B7.
2. lId
3. Id.
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biotechnology can play in developing countries, these countries
may not have sufficient access to this life-saving technology.
This Article introduces some of the economic, political, and
legal issues surrounding the use of biotechnology in developing
countries. Part II describes how biotechnology can aid developing
countries in eradicating hunger, poverty, and disease. Part III
examines developing countries' current access to biotechnology.
Part IV explores the primary barriers that impede developing
countries' access to biotechnology: lack of infrastructure, capital,
and trained scientists; lack of purchasing power; varying levels of
protection for intellectual property (IP) rights; and general
opposition to biotechnology. Part V discusses the current state of
the law, specifically the Paris Convention for the Protection of
Industrial Property, the General Agreement on Tariffs and Trade,
the Agreement on Trade-Related Aspects of Intellectual Property
Rights, the Convention on Biological Diversity, and U.S. House of
Representatives Resolution 2912. Part VI argues that solutions to
developing countries' limited access to biotechnology should be
sought through government action rather than through corporate
social responsibility.
II. ERADICATING HUNGER, POVERTY, AND DISEASE IN
DEVELOPING COUNTRIES THROUGH BIOTECHNOLOGY

In developing countries, 840 million people currently suffer4
from malnutrition and 1.3 billion are afflicted with poverty.
Approximately 30 to 40% of the people in these countries cannot
afford a diet consisting of the minimum amount of calories
necessary to ensure a healthy and active life. 5 In addition, 250
million children are at risk of vitamin A deficiency, which can6
result in learning disabilities and irreversible blindness.
Population growth threatens to intensify hunger and poverty in
developing countries. Global population is expected to double by

4.

CLIVE JAMES, GLOBAL STATUS OF COMMERCIALIZED TRANSGENIC CROPS:

2000 § 1 (Int'l Serv. for the Acquisition of Agri-biotech Application, Brief No. 21, 2000)
available at http://www.isaaa.org.
5. J.E.W.

BROERSE & T. VAN DE SANDE,

TECHNOLOGY TRANSFER

OR

ALTERNATIVE TECHNOLOGY, in 55 ISSUES IN AGRICULTURAL BIOETHICS, EASTER

SCHOOL SERIES IN AGRICULTURAL SCIENCES 361, 363 (B. Mepham, G. Tucker, and J.

Wiseman, eds., 1995).
6. Gordon Rausser et al., Public-private Alliances in Biotechnology: Can They
Narrow the Knowledge Gaps Between Rich and Poor? 25 FOOD POL'Y 500 (2000).
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2050, with 90% of the growth occurring in developing counties. 7
Life-threatening diseases, such as malaria, hookworm, sleeping
sickness, and schistosomiasis, also burden populations in
developing countries. 8 Biotechnology offers hopes of solving these
problems, primarily through GM crops and life-saving drugs.
GM crops can alleviate hunger and malnutrition in
developing countries by increasing developing countries' crop
yields. GM crops can increase crop yields because they can be
genetically engineered to resist the destructive conditions
prevalent in developing countries, such as insects, herbicides,
viruses, drought, and soil acidity. 9 To date, scientists have created
more than twenty plant species that are resistant to over thirty
different viral diseases. 10 In addition, they have engineered
herbicide-resistant canola, corn, cotton, maize, and soybean, 11 as
well as insect-resistant cotton, maize, potatoes, rice, sugarcane,
tobacco, tomatoes, and walnuts. 12 Although most of these crops
the same technology can
are not staples for developing countries, 13
be applied to developing countries' crops.
GM crops are more promising than traditional plant breeding
at increasing crop yields because traditional plant breeding may be
nearing its peak. Traditional plant breeding requires ample fresh
water and arable land in order to increase crop yields.
Unfortunately, both resources are decreasing rapidly. In fact,
during the last twenty-five years, misuse and overuse have
degraded more than one fourth of the world's agricultural lands,
pastures, forests, and woodlands. 14 In addition, experts have
warned that even with improved irrigation, the world needs 17%
more fresh water than is currently available, in order to meet its
food needs. 15 These figures suggest that traditional plant breeding
alone cannot sufficiently increase crop yields. In contrast, GM

7. Per Pinstrup-Anderson & Marc J. Cohen, Modern Biotechnology for Food and
Agriculture: Risks and Opportunitiesfor the Poor, 1999 AGRIC. BIOTECHNOLOGY AND
THE POOR: PROCEEDINGS OF THE INT'L CONF., WASH. D.C. 159, 160.
8. Jeffrey Sachs, Helping the World's Poorest, ECONOMIST, Aug. 14, 1999.
9. Id.
10. Luis Herrera-Estrella, Genetically Modified Crops and Developing Countries, 124
PLANT PHYSIOLOGY 923 (2000).
11. See JAMES, supra note 4, at 9-11.

12.
13.
14.
15.

Herrera-Estrella, supra note 10.
Id.
Id.
Id.
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crops can be genetically engineered to survive drought and
infertile soil. Therefore, they may be more effective than
traditional plant breeding at improving developing countries' crop
yields.
GM crops can also reduce hunger in developing countries by
preventing crops from spoiling before human consumption. Many
developing countries lose substantial amounts of tropical fruit
because they lack the necessary storage conditions and
16
transportation systems to deliver the fruit before spoilage.
Biotechnology can alleviate this problem by producing crops that
are genetically modified to delay ripening. In fact, scientists have
already created a delayed-ripening tomato, and may be able to
create delayed-ripening tropical fruits. 17 Through the use of such
GM crops, developing countries would be able to increase and
preserve crop yields.
Scientists can also use biotechnology to treat vitamin
deficiencies and life-threatening diseases in developing countries.
For example, scientists are currently able to enhance crops with
vital nutrients, such as vitamin A and iron. 18 In addition, recent
biotechnological advances, such as mapping the malaria genome,
suggest that scientists may be able to create vaccines for malaria
19
and other diseases.
Finally, developing countries can use biotechnology to boost
their economic growth and alleviate poverty. GM crops offer an
opportunity to improve agricultural programs in developing
countries, which can lead to increased employment opportunities,
greater self-sufficiency, and heightened economic stability. 20 These
possibilities are particularly important, considering that most
developing countries have a sizable agriculture sector and some
have agriculture-based economies. In Ethiopia, for example,
agriculture "accounts for half of the Gross Domestic Product
(GDP), 90% of exports, and 80% of total employment." '21 In
India, agriculture accounts for 25% of the GDP and 60% of total
16. Id. at 923.
17. Id.
18. Miguel A. Altieri, No: Poor Farmers Won't Reap the Benefits, 119 FOREIGN
POL'Y 123,123 (2000).
19. Sachs, supra note 8, at 17-18.
20. See Mark Strauss, When Malthus Meets Mendel, 119 FOREIGN POL'Y 105, 108
(2000).
21. CENTRAL INTELLIGENCE AGENCY, THE WORLD FACTBOOK (2002), availableat
http://www.odci.gov/cia/publications/factbook/geos/et.html (last visited Apr. 29,2003).
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employment. 22 Since these countries continue to lose arable land
and suffer from periods of drought, 23 GM crops that are immune
to these conditions could help stabilize and improve these
countries' economies. With poverty being the leading cause of
malnutrition, improved economies in developing countries could
also help solve their hunger problems.
Biotechnology promises to increase the quantity and quality
of food and drugs, which could alleviate hunger, vitamin
deficiencies, and disease in developing countries. In addition,
biotechnology may promote economic growth in developing
countries. But will developing countries have access to the
technology?
III. STATISTICS ON DEVELOPING COUNTRIES' ACCESS TO
BIOTECHNOLOGY

Developing countries currently lack sufficient access to
biotechnology in two respects. First, they do not have an adequate
Second,
quantity of biotechnology to address their needs.
developed countries, which conduct most biotechnology research
and development (R&D), create products for developed markets.
Therefore, most current biotechnology does not address problems
that are unique to developing countries.
The United States is currently the world leader in both the
production
and consumption of biotechnology. 24 U.S.
international patent filings demonstrate its dominance in the area
of biotechnology R&D. 25 In the first half of the 1990s, the United
States held priority of 63% of international biotechnology patents
26
and 59% of the most highly cited biotechnology inventions.
Federal grants and private industry are the two primary sources of
funding for biotechnology R&D in the United States. The United
States provides more funding for biotechnology R&D than any
private sector
other government in the world. Additionally, the
27
spends $18 billion a year on biotechnology R&D.

22- Id.
23. See id.
24. John M. Golden, Biotechnology, Technology Policy, and Patentability: Natural
Productsand Invention in the American System, 50 EMORY L.J. 101,107 (2001).
25. Id.
26. Id. at 107 n.27.
27. Id. at 107.
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The disparity in access to biotechnology is illustrated by the
global distribution of GM crops.
Between 1996 and 2000,
developed countries grew 85% of GM crops. 28
Although
developed countries possess most of the global GM crops,
developing countries' share of GM crops has been steadily
increasing. For example, from 1997 to 2000, developing countries'
share of GM crops increased from 14 to 24%.29
Despite increasing ownership, developing countries still lack
access to a majority of GM crops. In 2000, thirteen countries grew
GM crops-eight developed countries and five developing
countries. 30 The United States, Canada, Argentina and China
grew 99% of the global GM crop area.3 1 Of these countries, the
United States grew 68% of the global GM crop area. 32 Argentina,
Canada, and China grew 23%, 3 3 7%, and 1%, respectively. 34
These statistics demonstrate that most developing countries
continue to lack access to GM crops.
Since developed countries dominate biotechnology R&D,
most biotechnology advances do not address the needs of
developing countries. For example, most GM crops are not staple
foods, like rice and cassava, in developing countries. 35 Rather,
GM crops, like corn and cotton, are better suited for the U.S. and
European markets. 36 In fact, the four major GM crops grown
globally are soybean, corn, canola, and cotton. 37 Soybean, the
leading GM crop, constituted 58% of the global area of GM crops
in 2000.38 In addition, most GM crops are genetically modified to
increase crop yields in temperate zones, such as Europe and the
United States. 39 Developing
countries, however, need
biotechnology advances that are adapted to their native
environments. The technology should be geared to increase crop

28. JAMES, supra note 4, at 3.

29.
30.
31.
32.
33.
34.
35.
36.

Id.
Id. at 6.
Id.
Id.
Id.
Id.
Strauss, supra note 20, at 110.
Id.

37. JAMES, supra note 4, at 12.

38. Id. at 7.
39. Cf. Herrera-Estrella, supra note 10, at 924; Sachs, supra note 8, at 17-20 (stating
that the world's richest countries, i.e., developed countries, lie in temperate zones and GM
crops are genetically modified to increase crop yields in developed countries).
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yields in tropical and desert zones and engineered to be droughtresistant, 40
tolerable of saline soils and resistant to native diseases
pests.
and
The disparity between R&D aimed at developed and
developing countries needs is best illustrated by comparing the
budgets allocated to the two areas of research. Monsanto, a U.S.
biotechnology company that develops GM crops, allocates the
overwhelming majority of its budget toward improving temperatezone agriculture. 41 Monsanto is only one of the many
biotechnology companies that focus on temperate-zone
agriculture. Yet, Monsanto's R&D budget alone is twice the size
of the R&D budget for the entire worldwide network of publicsector tropical research institutes. 42 This disparity demonstrates
that R&D inadequately addresses developing countries' unique
agricultural needs.
Additionally, most medical-related biotechnology R&D fails
to address developing countries' needs because it targets the
ailments of developed countries, such as cancer and cardiovascular
disease. 43 Substantially less R&D is directed at ailments common
to developing countries, such as malaria, hookworm, sleeping
sickness, and schistosomiasis. 44 For example, the National Cancer
Institute (NCI) allocated $3.76 billion to its budget for cancer
research in 2001. 45 By contrast, NCI spends only $80 million per

year on malaria research. Additionally, biotechnological advances
point to the potential of a malaria vaccine. 46 Yet, of the worldwide
expenditures for biotechnology R&D, only a small fraction is
47
spent on vaccine research.
from
benefit greatly
could
Developing countries
biotechnology's promise of increased quantity and quality of food
and drugs. However, the above statistics show that developing
countries currently lack sufficient access to biotechnology,

40.
41.
42.
43.

See Herrera-Estrella, supra note 10, at 923; Sachs, supra note 8, at 17, 20.
Sachs, supra note 8, at 17, 19.
Id.
Sachs, supra note 8, at 17, 18.

44. Id.
45. National Cancer Institute, Message from the Director to NCI Grant Recipients
Regarding the FY 2001 Grant Funding Policy, at http://www.cancer.gov/scienceresources/
announcements/2001_funding-policy.htm (Mar. 1, 2001).
46. Sachs, supra note 8, at 17-19.
47. Id. at 17, 19.
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particularly in areas that would address these countries' unique
needs.
IV.

BARRIERS TO BIOTECHNOLOGY IN DEVELOPING COUNTRIES

Developing countries have limited access to biotechnology for
four main reasons. First, varying levels of IP protection affect
these countries' access to biotechnology. Strong IP protection
renders products too expensive for developing countries and
48
prevents researchers from gaining access to basic knowledge.
Conversely, weak IP protection discourages technology transfer,
foreign investment, and local creation. 49 Second, developing
countries lack the infrastructure, 50 capital, 51 and pool of trained
52
scientists necessary to develop their own biotechnology products.
Third, the private industry, which conducts the most biotechnology
R&D, is motivated by profit and sees no market in developing
to
Finally, anti-biotechnology groups object
countries. 53
54
increasing developing countries' access to biotechnology.
A. The Role of Intellectual Property Protection
IP rights present a unique challenge to developing countries
because patents can both hinder and further developing countries'
access to biotechnology. Patents give patent-holders a monopoly
on their technology for the term of the patent, which is typically
twenty years. 55 However, patent holders must publicly disclose
information about the technology, including how to construct and
utilize it.56 This disclosure requirement allows the public to
implement the technology as soon as the patent expires. The
rights is promotion of scientific 57
primary justification for patent
58
and technological progress.

48. See ROHINI ACHARYA, THE EMERGENCE AND GROWTH OF BIOTECHNOLOGY:
EXPERIENCES IN INDUSTRIALIZED AND DEVELOPING COUNTRIES 56 (1999).
49. Amy E. Carroll, Not Always the Best Medicine: Biotechnology and the Global
Impact of U.S. Patent Law, 44 AM. U. L. REV. 2433,2464 (1995).
50. ACHARYA, supra note 48, at 57.
51. Id.
52. Id.
53. Carroll, supra note 49, at 2463.
54. Id.
55. Id. at 2443 n.60.
56. See id. at 2447.
57. Id. at 2444 n.63.
58. See generally id. at 2439.
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Weak IP protection hinders developing countries' access to
biotechnology in two principal ways. First, weak IP protection
increases piracy, thereby discouraging developed countries from
exporting their biotechnology products to developing countries. 59
For example, a 1986 International Trade Commission (ITC) study
estimated that worldwide losses due to inadequate IP protection
were approximately $61 billion. 60 The ITC study further showed
that these losses caused U.S. industry to cut back employment and
R&D in developing countries. 61 Second, weak IP protection
obstructs domestic development in developing countries. For
example, weak IP protection discourages foreign investment and
technology transfer. 62 Additionally, it chills domestic creation by
decreasing incentives to invent. 63 Thus, in many ways, weak IP
protection
perpetuates
developing
countries'
lack
of
biotechnology.
Although strong IP protection may increase exports, foreign
investment, technology transfer, domestic creation, and
proprietary rights, it also limits developing countries' access to
biotechnology in two important ways. First, it increases the cost of
biotechnology because patent holders have no competitors during
the term of the patent. 64 Second, it restricts domestic and foreign
researchers' access to the basic science necessary to conduct R&D
that will benefit developing countries. 65 Thus, strong IP protection
can actually impede development in developing countries.
B. Lack of Infrastructure,Capital,and Trained Scientists
Biotechnology has been characterized as "one of the most
capital and research intensive industries in the history of civilian
manufacturing." 66 The cost of introducing a new GM crop to
market can range from $30 to $50 million. 67 Similarly, bringing
biotechnology-based
pharmaceuticals
to
market
costs

59. Id. at 2470.
60. Deborah Mall, The Inclusion of a Trade Related Intellectual Property Code Under
General Agreement on Tariffs and Trade (GATT), 30 SANTA CLARA L. REV. 265, 267
(1990).
61. Mall, supra note 60, at 267-68.
62. Carroll, supra note 49, at 2469.
63. Id.
64. See generally id. at 2443 n.59.
65. See id. at 2471.
66. Strauss, supra note 20, at 108.
67. Id.
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approximately a quarter of a billion dollars and takes four to seven
years. 68 Developing countries lack the government funding and
capital markets necessary to fund expensive biotechnology R&D.
69
For example, in 1988, India's total R&D budget was $2.5 million.
This is less than 5% of the capital needed to bring a new GM crop
to market, and less than 1% of the capital needed to bring a new
pharmaceutical to market.
Even if developing countries had adequate R&D funding,
they lack the infrastructure necessary to support biotechnology
development, including regulations, facilities, equipment,
transportation,
telecommunications,
training,
distribution
70
channels, and links between researchers and the industry.
Developing countries also lack trained scientists. For example, in
71
1988, India had only 3.12 researchers per 10,000 people.
Developing countries lack trained scientists for three reasons.
First, their national curricula, until very recently, did not include
biotechnology courses. 72 Second, they lack strength in basic
science and technology. 73 Finally, they have limited resources to
invest in training. 74 Some countries have attempted to solve these
problems by sending students abroad for training or by
collaborating with foreign universities and training institutions.
However, many countries cannot afford to do this. Plus, students
who train abroad often do not return to their native countries
75
because the foreign countries offer better resources.
Because developing countries lack capital, infrastructure, and
trained scientists, they are dependent on developed countries for
their biotechnology needs. 76 However, profit motives often hinder
developed countries from addressing those needs.

68. Carroll, supra note 49, at 2476.
69. ACHARYA, supra note 48, at 61.
70. Id. at 54-58.
71. Id. at 61.
72. Id. at 63.
73. Id. at 64.
74. Id.
75. See id. at 63-65.
76. See generally Ismael Serageldin, Biotechnology and Food Security in the 21st
Century, 285 Sa. 387 (1999).
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C. Privatizationof Biotechnology R&D and the Biotechnology
Industry's ProfitMotive
Three main players dominate biotechnology R&D: private
companies, governments, and universities. 77 Although each player
conducts its own research, governments and private companies
78
often supplement their research through funding to universities.
Generally, each player has different motives. A government's
primary motive is to advance the national interest in scientific and
technological progress. 79 A university's primary motive is to
conduct front-line science, which will increase its prestige and
ability to secure grants. 8081 Conversely, private companies seek
mainly to generate profits.
Today, private companies conduct most of the world's
biotechnology R&D, 82 accounting for 80% of all international
biotechnology research. 83 Since this industry's primary motivation
is profit, R&D investment is unlikely unless a viable market exists
for the resulting product. The enormous expense and timecommitment associated with biotechnology R&D exacerbates the
private industry's bias towards profit maximization. 84 Due to the
extreme poverty of developing countries, the biotechnology
industry does not perceive these countries as commercial
prospects. 85 Accordingly, the private industry creates few
86
biotechnology products aimed at developing countries' needs.

77. Golden, supra note 24, at 132.
78. Id
79. Id.
80. Id. at 134. In the early 1980s, Congress attempted to promote interaction between
the private companies, governments, and universities by passing legislation that
encouraged a "cooperative model" of R&D. For example, the Stevenson-Wydler Act
required federal laboratories to facilitate technology transfer to the industry. In addition,
the Bayh-Dole Act allowed government grantees and contractors to patent and sell
licenses to their inventions. Similarly, the Trademark Clarification Act of 1984 and the
Federal Technology Transfer Act of 1986 permitted government owned and operated
laboratories to enter Cooperative Research and Development Agreements with
nonfederal entities and required federal employees to receive a portion of patent royalties.
These government initiatives resulted in a trend towards public-private alliances. Id. at
119-22.
81. Id. at 133.
82. Strauss, supra note 20, at 110.
83. Id.
84. See id
85. See Herrera-Estrella, supra note 10, at 924.
86. See id.
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This is particularly problematic for developing countries because
the private industry conducts most biotechnology R&D. 87
Some biotechnology companies do assist developing countries
in gaining access to biotechnology. For example, Monsanto has
entered into agreements to develop virus-resistant crops with
government agricultural research institutes in Kenya and
Mexico. 88 In South Africa, Monsanto has also established a
farmer's academy, which teaches students the technical and
business aspects of farming. 89 In addition, several nonprofit
organizations help developing countries utilize biotechnology. For
example, over the past fifteen years, the Rockefeller Foundation
has funded approximately $100 million of plant biotechnology
research and scientist training in developing countries. 90 These
philanthropic companies and nonprofit organizations are removing
barriers to biotechnology in developing countries. Such companies
and organizations are rare, however, and their budgets pale in
comparison to the R&D budgets allocated for products in
91
developed countries.
D. Biotechnology Opponents
Some biotechnology advocates blame biotechnology
opponents for developing countries' limited access to
biotechnology.
For example, Dr. John Moyo, a Tanzanian
professor who works with the United Nation's Food and
Agriculture Organization stated, "[a]mong the many stumbling
blocks confronting scientists and policy makers in developing
countries is the unprecedented opposition to genetically modified
organisms by some elements of society, particularly those who
have never had to sleep on an empty stomach. '92 Wambugu
expressed
similar
beliefs,
stating,
"anti-biotechnology

87. Strauss, supra note 20, at 110; Herrera-Estrella, supra note 10, at 924; Sachs, supra
note 8, at 18.
88. Pinstrup-Anderson & Cohen, supra note 7, at 163.
89. MONSANTO FUND, GLOBAL CONTRIBUTIONS REPORT 4 (2000).
90. Rockefeller Foundation, Crop Biotechnology: Benefits, Risks and Ownership, at
http://www.rockfound.org/display.asp?context=l&Collection=4&DoclD=141&Preview
(Sept. 16,2002).
91. See Pinstrup-Anderson & Cohen, supra note 7, at 164 (comparing the Rockefeller
Foundation's $7.4 million agricultural program in developing countries in 1998 to
Monsanto's $1.3 billion budget for agricultural research that same year).
92. Agriculture: Member States Should be More Open to GMOS, Says Fischler, EUR.
REP. 470, Sept. 19, 2002, available at 2001 WL 26061565.
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protesters... would deny developing countries like my home,
Kenya, the resources to develop a technology
that can help
93
alleviate hunger, malnutrition and poverty."
Biotechnology opponents fear that GM crops will increase the
risk of famine by threatening biological diversity. 94 Reduced
biological diversity in developing countries is particularly
problematic because most of the world's biological diversity is
found in developing countries. Opponents also fear that GM crops
are unsafe, and that farmers in developing countries will become
95
dangerously dependent on them.
Opponents have launched anti-biotechnology campaigns in
order to conduct public protests and communicate their concerns.
For example, in April 2001, protesters set fire to Monsanto's
facilities in Italy. 96 In July 2001, thirty demonstrators from
Thailand's provinces protested the use of GM crops by dumping
garbage bins full of GM papayas, tomatoes, and corn on the steps
of the U.N. building. 97 Further, in August 2001, hundreds of
protesters in the Philippines destroyed GM corn grown by
98
Monsanto.
It is unclear whether opposition to biotechnology actually
impedes developing countries' access to biotechnology. However,
such opposition should be considered in assessing the barriers to
biotechnology in developing countries, along with three other
factors: lack of infrastructure, capital, and trained scientists;
privatization of biotechnology R&D and the industry's profit
motives; and IP rights. International treaties and national
legislation address some aspects of these barriers.

93. Florence Wambugu, Protesters Don't Help: Africa Needs Biotech to Combat
Hunger,TULSA WORLD, Nov. 18, 2001, at G3.
94. Altieri, supra note 18, at 123-24.
95. Id. at 123.
96. See Fire at Monsanto Plant in Italy, Company Blames Arsonists, AGENCE
FRANCE-PRESSE, April 3,2001, availableat 2001 WL 2376491.
97. British Deputy PM Defends Genetically Modified Crops, AGENCE FRANCEPRESSE, available at http'//www.monsanto.co.uk/new/ ukshowlib.phtml?uid=5383 (July 10,
2001).
98. Kitta MacPherson, A Rain of Hope for the Starving: Opponents Fear the
Consequences of Genetically EngineeredHybrid, STAR-LEDGER, Jan. 6, 2000, available at
2002 WL 3159013.
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V. CURRENT STATE OF THE LAW

There is no international law that requires developed
countries to share their biotechnology with developing countries.
However, some international treaties and certain U.S. legislation
address issues relevant to biotechnology and technology transfer in
developing countries.
For example, the Paris International
Convention (Paris Convention), the General Agreement on
Tariffs and Trade (GATT), and the Agreement on Trade Related
Aspects of Intellectual Property Rights (TRIPS) address
international IP issues in the context of trade. Similarly, the
Convention on Biological Diversity addresses international IP
99
issues in the context of conserving biological diversity.
Furthermore, the U.S. Congress is currently considering House of
Representatives Resolution 2912, a bill that would create
incentives for U.S. institutions to transfer technology to
100
developing countries.
A. Paris,GATT, and TRIPS
The first global discussion of patent law occurred in 1883 at
the Paris International Convention for the Protection of Industrial
Property. 10 1
The Paris Convention established two basic
principles: national treatment and international priority. 10 2 The
principle of national treatment requires member countries to
provide nationals of other member countries with patent rights at
least as good as they give their own nationals. 10 3 The principle of
international priority allows patent applicants, who file in a Paris
Convention country, to use the filing date as a priority date in
every other member country, provided the second filing occurs
within twelve months of the first filing. 1°4 Although the Paris
Convention established national treatment and international
priority, it contains few provisions concerning minimum rights.
For example, it does not specify the duration or subject matter of
patents. In fact, it does not even require countries to protect

99. Convention on Biological Diversity, June 4, 1993, art. 1, S. TREATY Doc. No.
103-20.
100. H.R. 2912, 107th Cong. §2 (2001).
101. See Mall, supra note 60, at 266 n.8.
102. See Paris Convention for the Protection of Industrial Property, July 14, 1967, arts.
2, 4, 53 Stat. 1748, 828 U.N.T.S. 305 [hereinafter Paris Convention].
103. Paris Convention, supra note 102, art. 2, 53 Stat. at 1748, 828 U.N.T.S. at 305.
104. Id. art. 4,53 Stat. at 1748, 828 U.N.T.S. at 305.
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patents. Moreover, the Paris Convention lacks enforcement
mechanisms and dispute resolution methods. 105
In 1967, the World Intellectual Property Organization
(WIPO) was established to enforce international IP agreements,
including the Paris Convention. 10 6 Developed countries, however,
were dissatisfied with WIPO's enforcement. 107 Thus, they sought
to include trade related IP rights in GATT. Their efforts resulted
in the incorporation of the Agreement on Trade Related Aspects
of Intellectual Property Rights (TRIPS Agreement) into GATT,
thus subjecting TRIPS to GATT's dispute resolution and
10 8
enforcement mechanisms.
The TRIPS Agreement establishes a minimum level of IP
protection which member countries must implement.
For
example, members must make patents "available for any
inventions, whether products or processes, in all fields of
technology, provided they are new, involve an inventive step, and
are capable of industrial application.' 1 9 Additionally, members
must recognize patent holders' exclusive rights to make, use, offer
for sale, sell, and import their products or processes. 110 These
provisions, however, create problems for developing countries,
which lack the resources necessary to implement the required
minimum levels of IP protection. In addition, some developing
countries depend on inexpensive, generic versions of patented
drugs to treat health problems, such as AIDS. 111
TRIPS recognizes these problems and addresses them
through three provisions in a declaration at the World Trade
Organization (November WTO declaration) in November 2001.
First, the TRIPS Agreement gives the world's least developed
countries until 2005 to implement its minimum levels of IP
protection. 112 In November 2001, this deadline was extended to

105.
106.
107.
108.
109.

See id.
Carroll, supra note 49, at 2457.
Id. at 2458.
Mall, supra note 60, at 279.
Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15,

1994, art. 27, reprinted in INTERNATIONAL TREATIES ON INTELLECTUAL PROPERTY 599

(Marshall A. Leaffer ed., BNA Books 2d ed. 1997) [hereinafter TRIPS Agreement].
110. TRIPS Agreement, supra note 109, art. 28.
111. Tina Rosenberg, Look at Brazil, N.Y. TIMES MAG., Jan. 28, 2001, at 28.
112. TRIPS Agreement, supra note 109, art. 66.
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2016.113 Second, TRIPS states that "[d]eveloped country Members
shall provide incentives to enterprises and institutions in their
territories for the purpose of promoting and encouraging
technology transfer to least-developed country Members in order
114
to enable them to create a sound and viable technological base."
115
The November WTO declaration reaffirmed this requirement.
Finally, TRIPS allows countries to grant compulsory licenses for
patented products and processes "in the case of a national
'116
emergency or other circumstances of extreme urgency.
Compulsory licenses allow parties to make certain uses out of
patented products and processes without the patent holder's
permission, provided that the parties pay the patent holder
"adequate remuneration." 117 TRIPS, however, does not define
"adequate remuneration."' 118
Signatories to TRIPS are reluctant to grant compulsory
licenses due to fear of trade sanctions. 119 The November WTO
declaration, however, makes clear that TRIPS permits compulsory
licenses. 120 Specifically, the declaration states that a "[m]ember
has the right to grant compulsory licenses" as well as "the right to
determine what constitutes a national emergency or other
circumstances of extreme urgency" such as "public health
12 1
crises."
Most developing countries are signatories to GATT and
TRIPS. 122 Developed countries, which are responsible for most of
the biotechnology R&D, such as the United States, Canada, and
the European Union are also signatories to GATT and TRIPS.
Therefore, GATT" and TRIPS are particularly relevant to
developing countries' access to biotechnology.

113. Declaration on the TRIPS Agreement and Public Health, WT/MIN(01)/DEC2,
at http:/www.wto.org/english/thewto_e/ministe/min0le/ minOle.htm., (Nov. 20, 2001)
[hereinafter TRIPS Declaration].
114. TRIPS Agreement, supra note 109, art. 66.
115. TRIPS Declaration, supra note 113.
116. TRIPS Agreement, supra note 109, art. 31(b).
117. TRIPS Agreement, supra note 109, art. 31(h).
118. See Rosenberg, supra note 111, at 31.
119. Id. at 31, 52.
120. TRIPS Declaration, supra note 113.
121. Id.
122. INTERNATIONAL TREATIES ON INTELLECTUAL PROPERTY 587 (Marshall A.
Leaffer ed., BNA Books 2d ed. 1997).
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B. Convention on Biological Diversity

While TRIPS, GATT, and the Paris Convention address
international IP issues in the context of trade, the Convention on
Convention)
addresses
Diversity
(Biodiversity
Biological
international IP issues in the context of preserving biological
diversity.' 23 The Biodiversity Convention established strategies,
plans and programs to conserve biological diversity and its
sustainable use. It also addresses IP issues affecting developing
countries. 124 In Article 15, the Biodiversity Convention recognizes
countries' proprietary rights to their natural resources:
Recognizing the sovereign rights of States over their natural
resources, the authority to determine access to genetic
resources rests with the national governments and is subject to
national legislation.... Access, where granted shall be on
mutually agreed terms and subject to the provisions of this
Article. Access to genetic resources shall be subject to prior
informed consent of the Contracting Party providing such
resources, unless otherwise determined by that Party.... Each
Contracting Party shall take legislative, administrative or policy
measures, as appropriate.., with the aim of sharing in a fair
and equitable way the results of research and development and
the benefits arising from the commercial and other utilization of
genetic resources with the Contracting Party providing such
Such sharing shall be upon mutually agreed
resources.
12 5
terms.
This provision is significant because many of the natural resources
used in biotechnology products are found in developing countries.
Article 16 requires developed countries to transfer technology
to developing countries:
Each Contracting Party, recognizing that technology includes
biotechnology, and that both access to and transfer of
technology among Contracting Parties are essential elements
for the attainment of the objectives of this Convention,
undertakes subject to the provisions of this Article to provide
and/or facilitate access for and transfer to other Contracting
Parties of technologies that are relevant to the conservation and
sustainable use of biological diversity or make use of genetic

123. Convention on Biological Diversity, June 4, 1993, art. 1, S. TREATY DOc. No.
103-20.
124. 1l art. 6.
125. Id. art. 15.
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resources and do not cause significant damage to the
environment ....In the case of technology subject to patents
and other intellectual property rights, such access and transfer
shall be provided on terms which recognize and are consistent
with the adequate and effective protection of intellectual
property rights ....Each Contracting Party shall take
legislative, administrative or policy measures, as appropriate,
with the aim that Contracting Parties, in particular those that
are developing countries, which provide genetic resources are
provided access to and transfer of technology which makes use
of those resources, on mutually agreed terms, including
technology protected by patents and other intellectual property
rights, where necessary ....126

Articles 15 and 16 of the Biodiversity Convention are
enforceable through Article 27, which provides for optional
recourse to the International Court of Justice and/or arbitration,
and mandatory recourse, at the request of one party to a dispute,
127
to nonbinding conciliation.
On its face, the Biodiversity Convention is extremely
promising for developing countries. However, in practice it has
done little to increase developing countries' access to
biotechnology for two major reasons. First, the United States,
which dominates biotechnology R&D, signed the convention on
June 4, 1993, but has yet to ratify it. Second, the convention's
provisions are ambiguous. For example, signatories must take
legislative, administrative, and policy measures "as appropriate"
and must share the results of R&D "in a fair and equitable
way.' 12 8
These vague phrases makes enforcement of the
convention difficult. 129

C. U.S. House of RepresentativesResolution 2912
The United States has attempted to increase developing
countries' access to biotechnology through legislation, such as U.S.
House of Representatives Resolution 2912 (H.R. 2912). H.R. 2912
authorizes the National Science Foundation (NSF) to establish a
grant program for partnerships between U.S. research

126. Id. art. 16.
127. Id.
128. Id. art. 15, sec. 7.
129. Chris Wold, The Futility, Utility, and Future of the Biodiversity Convention, 9
COLO. J. INT'L ENVTL. L. & POL'Y 1, 7 (1998).
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organizations and research organizations in developing countries
for research on plant biotechnology. 130 Specifically, H.R. 2912
authorizes the appropriation of $6 million to the NSF for fiscal
year 2002, $9 million for fiscal year 2003, and $9 million for fiscal
year 2004.131
H.R. 2912 further specifies that the NSF shall award grants to
institutions of higher education or nonprofit organizations to
establish research partnerships with developing countries. 132 The
resolution further specifies that these research partnerships shall
focus on developing plant biotechnology that targets developing
countries' needs. 133 H.R. 2912 also explicitly condones the use of
the grant money for the following: conducting basic genomic
research on crops in developing countries; developing plant
biotechnology that will advance and expedite the development of
improved cultivars, including those that are pest-resistant, produce
increased yield, or increase stress-tolerance; developing
technologies to produce pharmaceutical compounds, such as
vaccines and medications, in plants that can be grown in
developing countries; and researching plant biotechnology's
impact on the social, political, and economic conditions in
134
developing countries.
H.R. 2912 would improve developing countries' access to
biotechnology. However, it is unclear whether Congress will pass
it. The resolution was introduced on September 20, 2001135 when
it was immediately assigned to the House Committee on Science.
136
To date, no further action has been taken.
VI. SHIFTING THE DISCUSSION AWAY FROM CORPORATE SOCIAL

RESPONSIBILITY AND TOWARD GOVERNMENT ACTION

Some commentators focus on the social responsibility of
private companies to transfer biotechnology to developing
countries; 137 however, this may not be an appropriate role for
corporations. Corporations have a legal duty to maximize wealth
130. H.R. 2912, 107th Cong. (2001).
131. Id. § 3.
132- Id. § 2(a).
133. See id § 2(c).
134. Id § 2(c).
135. H.R. 2912,107th Cong. (2001).
136. Id
137. See Strauss, supra note 20, at 105; see also Rosenberg, supra note 111, at 26; Sachs,
supra note 8.
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for their shareholders. 138 In some cases, this duty may conflict
with the notion that corporations should transfer technology to
developing countries. For example, Monsanto's philanthropic
projects in developing countries provide some economic benefits
to Monsanto's shareholders, such as company goodwill,
advertising, and new markets. 139 If the economic costs of
Monsanto's philanthropic projects outweigh these economic
benefits, however, then Monsanto's board of directors may have
breached their duty to their shareholders.
Of course, the
shareholders are unlikely to prevail in a suit against the directors
because the costs and benefits are difficult to quantify and the
directors are protected by the business judgment rule. However,
this example demonstrates that corporations' duties are to their
shareholders, not the general welfare of society. Accordingly, we
should not look to the biotechnology industry to increase
developing countries' access to biotechnology. Instead, we should
look to government.
The U.S. government can increase developing countries'
access to biotechnology in two important ways. First, it can ratify
the Biodiversity Convention and satisfy its obligations under the
Convention. These obligations include respecting developing
countries' proprietary rights to their genetic resources, sharing
R&D with developing countries, and transferring technology to
developing countries. 140 Because the United States conducts most
of the world's biotechnology R&D, developing countries would
benefit substantially if the United States adopted and fulfilled its
obligations under the Biodiversity Convention.
Second, the United States can provide organizations and
corporations financial incentives to build infrastructure, transfer
technology, train scientists, and invest in developing countries.
For example, Congress should pass H.R. 2912. Additionally,
public agencies should offer similar grants to institutions that assist
developing countries in building infrastructure, training scientists,
and conducting R&D. The U.S. Congress should also offer tax
breaks to corporations, like Monsanto, that establish programs to
further developing countries' access to biotechnology.

138. CHARLES R.T. O'KELLEY & ROBERT B. THOMPSON, CORPORATIONS AND
OTHER BUSINESS ASSOCIATIONS CASES AND MATERIALS, 261 (1999).
139. See MONSANTO FUND, GLOBAL CONTRIBUTIONS REPORT (2000).

140. Id.
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To ensure the efficacy of these assistance programs, the U.S.
Congress should prioritize building infrastructure and training
scientists. Then, they should concentrate on assisting developing
countries with implementing simple biotechnology techniques that
focus on the crops and drugs most important to each individual
country. Financial incentives and tax breaks are preferable to
direct foreign aid because they offer permanent changes.
Developing countries with biotechnology infrastructure and
trained scientists will no longer be dependent on developed
countries for their biotechnology needs.
Taxpayers may oppose using public funds to assist developing
countries. However, TRIPS states that the United States shall
provide its industries with incentives to promote technology
transfer to developing countries. Therefore, if the United States
does not use public funds to incentivize technology transfer to
developing countries, it may be in violation of TRIPS.
VII. CONCLUSION

Biotechnology offers hopes of eliminating hunger, poverty,
and disease in developing countries. These countries, however,
lack sufficient access to biotechnology because they lack the
resources to produce it and the money to buy it.
The
biotechnology industry, which controls most of the biotechnology
R&D, will not address developing countries' needs because
corporations' role in society is to maximize their shareholders'
wealth, and developing countries are not a profitable market.
Therefore, it is futile to look to the biotechnology industry to
increase developing countries' access to biotechnology. Instead,
we must look to our government which can further the interests of
developing countries by ratifying treaties, like the Biodiversity
Convention, and passing legislation, like H.R. 2912.

